Absci Corporation - Common Stock (ABSI)
3.7100
-0.1100 (-2.88%)
Absci Corp is a biotechnology company that focuses on advancing the development of protein-based therapeutics through its innovative AI-driven platform
The company combines synthetic biology with machine learning to enhance the discovery, design, and production of complex proteins and antibodies. Absci’s technology aims to revolutionize the way biologic drugs are developed, enabling faster and more efficient creation of new drug candidates to address unmet medical needs in various therapeutic areas. By leveraging its proprietary platform, Absci aims to support pharmaceutical and biotech partners in bringing next-generation therapies to market.
Previous Close | 3.820 |
---|---|
Open | 3.900 |
Bid | 3.700 |
Ask | 3.750 |
Day's Range | 3.630 - 4.010 |
52 Week Range | 2.450 - 6.720 |
Volume | 3,554,782 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 7,529,598 |
News & Press Releases
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Salesbenzinga.com
Via Benzinga · January 22, 2025
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upsidebenzinga.com
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.
Via Benzinga · January 22, 2025
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earningsbenzinga.com
Via Benzinga · January 22, 2025
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · January 22, 2025
Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)benzinga.com
Via Benzinga · January 17, 2025
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
By Absci Corporation · Via GlobeNewswire · January 22, 2025
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · January 22, 2025
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policiesbenzinga.com
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.
Via Benzinga · January 22, 2025
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
By Absci Corporation; Owkin · Via GlobeNewswire · January 10, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 8, 2025
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · January 8, 2025
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discoverybenzinga.com
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators and ROCm software.
Via Benzinga · January 8, 2025
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
By Absci Corporation · Via GlobeNewswire · January 8, 2025
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
By Absci Corporation; Invetx · Via GlobeNewswire · January 6, 2025
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
By Absci Corporation · Via GlobeNewswire · January 2, 2025
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia
By Absci Corporation · Via GlobeNewswire · December 12, 2024
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · December 12, 2024
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · December 10, 2024
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.
By Absci Corporation · Via GlobeNewswire · November 21, 2024
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
By Absci Corporation · Via GlobeNewswire · November 12, 2024
Absci to Host R&D Day on December 12, 2024
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
By Absci Corporation · Via GlobeNewswire · November 7, 2024
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
By Absci Corporation · Via GlobeNewswire · October 31, 2024
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
By Absci Corporation · Via GlobeNewswire · October 24, 2024